Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/65757
Title: Long-term functional improvements in the 2-year treatment of schizophrenia outpatients with olanzapine long-acting injection 
Author: Ascher-Svanum, Haya
Novick, Diego
Haro Abad, Josep Maria
Bertsch, Jordan
McDonnell, David
Detke, Holland
Keywords: Antipsicòtics
Esquizofrènia
Qualitat de vida
Antipsychotic drugs
Schizophrenia
Quality of life
Issue Date: 20-Jun-2014
Publisher: Dove Medical Press
Abstract: BACKGROUND: Little is known about the long-term changes in the functioning of schizophrenia patients receiving maintenance therapy with olanzapine long-acting injection (LAI), and whether observed changes differ from those seen with oral olanzapine. METHODS: This study describes changes in the levels of functioning among outpatients with schizophrenia treated with olanzapine-LAI compared with oral olanzapine over 2 years. This was a secondary analysis of data from a multicenter, randomized, open-label, 2-year study comparing the long-term treatment effectiveness of monthly olanzapine-LAI (405 mg/4 weeks; n=264) with daily oral olanzapine (10 mg/day; n=260). Levels of functioning were assessed with the Heinrichs-Carpenter Quality of Life Scale. Functional status was also classified as 'good', 'moderate', or 'poor', using a previous data-driven approach. Changes in functional levels were assessed with McNemar's test and comparisons between olanzapine-LAI and oral olanzapine employed the Student's t-test. RESULTS: Over the 2-year study, the patients treated with olanzapine-LAI improved their level of functioning (per Quality of Life total score) from 64.0-70.8 (P<0.001). Patients on oral olanzapine also increased their level of functioning from 62.1-70.1 (P<0.001). At baseline, 19.2% of the olanzapine-LAI-treated patients had a 'good' level of functioning, which increased to 27.5% (P<0.05). The figures for oral olanzapine were 14.2% and 24.5%, respectively (P<0.001). Results did not significantly differ between olanzapine-LAI and oral olanzapine. CONCLUSION: In this 2-year, open-label, randomized study of olanzapine-LAI, outpatients with schizophrenia maintained or improved their favorable baseline level of functioning over time. Results did not significantly differ between olanzapine-LAI and oral olanzapine.
Note: Reproducció del document publicat a: http://dx.doi.org/10.2147/NDT.S61409
It is part of: Neuropsychiatric Disease And Treatment, 2014, vol. 10, p. 1125-1131
Related resource: http://dx.doi.org/10.2147/NDT.S61409
URI: http://hdl.handle.net/2445/65757
ISSN: 1176-6328
Appears in Collections:Articles publicats en revistes (Psicologia Clínica i Psicobiologia)

Files in This Item:
File Description SizeFormat 
649059.pdf211.67 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons